

**Supplementary table 6: Participants above seropositivity threshold before first (*pre*) and 3 months after last vaccination (*post*) per HPV type**

	HPV16		HPV18		HPV31		HPV33		HPV45		HPV52		HPV58	
	<i>pre</i>	<i>post</i>	<i>pre</i>	<i>post</i>	<i>pre</i>	<i>post</i>	<i>pre</i>	<i>post</i>	<i>pre</i>	<i>post</i>	<i>pre</i>	<i>post</i>	<i>pre</i>	<i>post</i>
<b>qHPV group (n=64)</b>	42/64 (66%)	64/64 (100%)	45/64 (70%)	64/64 (100%)	31/64 (48%)	50/64 (78%)	30/64 (47%)	49/64 (77%)	33/64 (52%)	56/64 (88%)	20/64 (31%)	38/64 (59%)	19/64 (30%)	45/64 (70%)
<b>Placebo group (n=62)</b>	42/62 (68%)	48/62 (77%)	43/62 (69%)	40/62 (65%)	20/62 (32%)	16/62 (26%)	29/62 (47%)	34/62 (55%)	34/62 (55%)	35/62 (56%)	16/62 (26%)	15/62 (24%)	20/62 (32%)	18/62 (29%)

Data are n/N (%). No seropositivity thresholds are available for HPV6 and 11.

Abbreviation: HPV, human papillomavirus; qHPV, quadrivalent human papillomavirus vaccine